Duration of adjuvant trastuzumab: shorter beats longer

Affiliations

Comment

Heikki Joensuu. Lancet. 2013.

. 2013 Sep 21;382(9897):1010-1.

doi: 10.1016/S0140-6736(13)61448-8. Epub 2013 Jul 18.

¹ Department of Oncology, Helsinki University Central Hospital and Helsinki University, Haartmaninkatu 4, FIN-00029 Helsinki, Finland. heikki.joensuu@hus.fi

No abstract available

Comment on

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J; Herceptin Adjuvant (HERA) Trial Study Team. Goldhirsch A, et al. Lancet. 2013 Sep 21;382(9897):1021-8. doi: 10.1016/S0140-6736(13)61094-6. Epub 2013 Jul 18. Lancet. 2013. PMID: 23871490 Clinical Trial.